Belgia - Inggris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mundipharma bv-srl - fluticasone propionate 0,125 mg; sodium cromoglicate 0,024 mg; formoterol fumarate dihydrate 0,005 mg - pressurised inhalation, suspension - 125 µg - 5 µg - fluticasone propionate 125 µg; formoterol fumarate dihydrate 5 µg - formoterol and fluticasone

Belgia - Inggris - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

mundipharma bv-srl - fluticasone propionate 0,125 mg/dose; formoterol fumarate dihydrate 0,005 mg/dose - pressurised inhalation, suspension - 125 µg/dose - 5 µg/dose - fluticasone propionate 0.125 mg/dose; formoterol fumarate dihydrate 0.005 mg/dose - formoterol and fluticasone

Kanada - Inggris - Health Canada

pharmascience inc - fluticasone propionate - metered-dose aerosol - 50mcg - fluticasone propionate 50mcg - adrenals

Kanada - Inggris - Health Canada

pharmascience inc - fluticasone propionate - metered-dose aerosol - 250mcg - fluticasone propionate 250mcg - adrenals

Kanada - Inggris - Health Canada

pharmascience inc - fluticasone propionate - powder - 100mcg - fluticasone propionate 100mcg - adrenals

Kanada - Inggris - Health Canada

pharmascience inc - fluticasone propionate - powder - 250mcg - fluticasone propionate 250mcg - adrenals

Kanada - Inggris - Health Canada

pharmascience inc - fluticasone propionate - powder - 500mcg - fluticasone propionate 500mcg - adrenals

Selandia Baru - Inggris - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 20mg equivalent to 125 µg/dose;  ; salmeterol xinafoate 5.8mg equivalent to 25 µg/dose salmeterol;   - aerosol inhaler, metered dose - 125µg/25µg - active: fluticasone propionate 20mg equivalent to 125 µg/dose   salmeterol xinafoate 5.8mg equivalent to 25 µg/dose salmeterol   excipient: norflurane - seretide is indicated in the regular treatment of reversible obstructive airways disease (road), including asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) is appropriate. this may include: patients on effective maintenance doses of long-acting ?-agonists and inhaled corticosteroids. patients who are symptomatic on current inhaled corticosteroid therapy. patients who are symptomatic on "as needed" short-acting betaagonists, as an alternative to initiation of maintenance therapy with moderate or high doses of inhaled corticosteroid alone.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - fluticasone propionate, quantity: 250 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for use in the prophylactic management of asthma in adults and adolescents over 16 years of age.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - fluticasone propionate, quantity: 125 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for use in the prophylactic management of asthma in adults and adolescents over 16 years of age.